Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.34 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18309358 | 0.90 | LMNA (0.44) | LMNASMN1; SMN2KDM4EPOLBRORC | |
| SCHEMBL17034780 | 0.85 | LMNA (0.42) | LMNASMN1; SMN2KDM4EPOLBRORC | |
| SCHEMBL13472162 | 0.80 | CYP1A2 (0.46) | LMNASMN1; SMN2ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL18309361 | 0.80 | LMNA (0.50) | LMNASMN1; SMN2KDM4EPOLBRORC | |
| SCHEMBL20307140 | 0.78 | LMNA (0.45) | LMNASMN1; SMN2KDM4EPOLBRORC | |
| SCHEMBL20434830 | 0.78 | RIPK1 (0.37) | SMN1; SMN2ALDH1A1CYP2C9EPHX2CYP3A4 | |
| SCHEMBL17177250 | 0.78 | LMNA (0.47) | LMNASMN1; SMN2RORCGAAALDH1A1 | |
| SCHEMBL15128218 | 0.75 | CYP3A4 (0.42) | SMN1; SMN2ALDH1A1CYP1A2CYP2D6EPHX2 | |
| SCHEMBL30143045 | 0.75 | SPR (0.37) | SMN1; SMN2KDM4EPOLBGAAALDH1A1 | |
| SCHEMBL28186001 | 0.74 | LMNA (0.60) | LMNASMN1; SMN2KDM4EPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362398-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362398-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, CFH | LMNA 2178/4885SMN1; SMN2 2038/4885KDM4E 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.